In-Licensing in Specialty Pharma
Executive Summary
The emerging sector of specialty pharma-companies building a business around in-licensing poorly penetrated drugs and growing their share through targeted sales efforts-represents an increasing percentage of total dealmaking volume. But could its strategy already be suffering from diminishing returns?
You may also be interested in...
Specialty Pharma: Eating Big Pharma's Lunch, Not Just its Leftovers?
While not yet rivals to Big Pharma when it comes to clinical-stage licensing, spec pharmas have in some individual cases proven to be more favored partners than their Big Pharma competitors.
In-Licensing in Specialty Pharma, Revisited
Trends in licensing volume and value by specialty pharma in-licensers.
In-Licensing in Specialty Pharma, Revisited
Trends in licensing volume and value by specialty pharma in-licensers.